Room for improvement in the pharmacological treatment of anxiety disorders

Current Pharmaceutical Design

Volumn 14, Issue 33, 2008, Pages 3482-3491

  Baldwin, D S ^a  

^a ROYAL SOUTH HANTS HOSPITAL   (United Kingdom)

Author keywords

Anxiety disorder; CBT; Recognition; Response; SSRI; Tolerability; Treatment

Indexed keywords

AGOMELATINE; ALPRAZOLAM; BUSPIRONE; CYCLOSERINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; IMIPRAMINE; LORAZEPAM; MOCLOBEMIDE; PAROXETINE; PHENELZINE; PINDOLOL; PLACEBO; PREGABALIN; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRIFLUOPERAZINE; VENLAFAXINE;

ANXIETY DISORDER; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; NAUSEA; NERVOUSNESS; OPTIMAL DRUG DOSE; PREDICTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECURRENCE RISK; REMISSION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; TREATMENT DURATION; WEIGHT GAIN;

ANXIETY DISORDERS; CLINICAL TRIALS AS TOPIC; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 59849102458     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786848810     Document Type: Review

References (93)

1. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson J, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: Recommendations from the British association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-96.
2. Haynes RB, Devereaux PJ, Guyatt GH. Physicians' and patients' choices in evidence based practice. BMJ 2002; 324: 1350.
3. National Institute for Clinical Excellence. The management of panic disorder and generalised anxiety disorder in primary and secondary care. National Collaborating Centre for Mental Health: London; 2004.
4. National Institute for Clinical Excellence. Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphophobic disorder. National Collaborating Centre for Mental Health: London; 2005.
5. National Institute for Clinical Excellence. Post-traumatic stress disorder. The management of PTSD in adults and children in primary and secondary care. National Clinical Practice Guideline number 26. The Royal College of Psychiatrists and the British Psychological Society: London; 2005.
6. Guy W. The clinical global impression severity and impression scales. ECDEU Assessment Manual for Psychopathology. Rockville, MD. US Dept Health: Education and Welfare 1976; 218-22.
7. Baldwin DS, Ajel K. The role of pregabalin in the treatment of generalized anxiety disorder. Neuropsychiatric Dis Treat 2007; 3: 185-91.
8. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32: 50-55.
9. Baldwin DS, Huusom AKT, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder. Randomised, double-blind, placebo-controlled study. Br J Psychiatry 2006; 189: 264-72.
10. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 2006; 67: 1428-34.
11. Rickels K, Rynn M, Iyengar M, Duff D. Remission of generalized anxiety disorder: A review of the paroxetine clinical trials database. J Clin Psychiatry 2006; 67: 41-7.
12. Hidalgo RB, Tupler LA, Davidson JRT. An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol 2007; 21: 864-72.
13. Mitte K, Noack P, Steil R, Hautzinger M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol 2005; 25: 141-50.
14. Heimberg RG. Cognitive-behavioral therapy for social anxiety disorder: current status and future directions. Biol Psychiatry 2002; 51: 101-08.
15. Blanco C, Raza MS, Schneier F, Liebowitz MR. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol 2003; 6: 427-42.
16. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs atenolol in social phobia; a placebo controlled comparison. Arch Gen Psychiatry 1992; 49: 290-300.
17. Baldwin DS, Bobes J, Stein DJ, Scharwachter I, Faure M. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Br J Psychiatr 1999; 175: 120-26.
18. Lader M, Stender K, Burger V, Nil R. Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anx 2004; 19: 241-8.
19. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjödin I, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004; 19: 387-96.
20. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005; 62: 190-8.
21. Liebowitz MR, Stein MB, Tancer M. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. J Clin Psychiatry 2002; 63: 66-74.
22. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. J Clin Psychopharmacol 2004; 24: 141-9.
23. Hedges DW, Brown BL, Shwalb DA, Godfrey K, Larcher AM. The efficacy of selective serotonin reuptake inhibitors in adult social anxiety disorder: A meta-analysis of double-blind, placebo-controlled trials. J Psychopharmacol 2007; 21: 102-11.
24. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry 1999; 60 (Suppl 22): 29-34.
25. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: A 6-month randomized controlled trial. Psychopharmacology 2005; 177: 280-8.
26. Wagner KD, Berard R, Stein MB, Wetherhold E, Carpenter DJ, Perera P, et al. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 2004; 61: 1153-62.
27. Perugi G, Frare F, Toni C, Ruffolo G, Torti C. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid depression or dysthymia: Effectiveness, tolerability and predictors of response. Neuropsychobiology 2002; 46: 145-9.
28. Simon NM, Zalta AK, Worthington JJ 3rd, Hoge EA, Christian KM, Stevens JC, et al. Preliminary support for gender differences in response to fluoxetine for generalized anxiety disorder. Depress Anx 2006; 23: 373-6.
29. Rodriguez BF, Weisberg RB, Pagano ME, Bruce SE, Spencer MA, Culpepper L, et al. Characteristics and predictors of full and partial recovery from generalized anxiety disorder in primary care patients. J Nerv Ment Dis 2006; 194: 91-7.
30. Pollack MH, Meoni P, Otto MW, Simon N, Hackett D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: A pooled analysis of short-and long-term studies. J Clin Psychopharmacol 2003; 23: 250-9.
31. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B. Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006; 67: 1741-6.
32. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001; 62: 523-9.
33. Stein DJ, Andersen HF, Goodman WK. Escitalopram for the treatment of GAD: Efficacy across different subgroups and outcomes. Ann Clin Psychiatry 2005; 17: 71-75.
34. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pre-gabalin in depressive symptoms associated with generalized anxiety disorder: A pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008; 18: 422-30.
35. Olatunji BO, Feldman G, Smits JA, Christian KM, Zalta AK, Pollack MH, et al. Examination of the decline in symptoms of anxiety and depression in generalized anxiety disorder: Impact of anxiety sensitivity on response to pharmacotherapy. Depress Anx 2008; 25: 167-71.
36. Downing RW, Rickels K. Early treatment response in anxious outpatients treated with diazepam. Acta Psychiatr Scand 1985; 72: 522-8.
37. Laakmann G, Schüle C, Lorkowski G, Baghai T, Kuhn K, Ehrentraut S. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacol 1998; 136: 357-66.
38. Rynn M, Khalid-Khan S, Garcia-Espana JF, Etemad B, Rickels K. Early response and 8-week treatment outcome in GAD. Depress Anx 2006; 23: 461-5.
39. Pollack MH, Kornstein SG, Spann ME, Crits-Christoph P, Raskin J, Russell JM. Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint. J Psychiatr Res 2008; E-pub ahead of print.
40. Baldwin DS, Stein DJ, Dolberg O, Bandelow B. How long should an initial treatment period be in anxiety disorders and in major depressive disorder? Presented at International Anxiety Disorders Symposium (IADS) Cape Town, South Africa, 17-18 March 2008.
41. Scholing A, Emmelkamp PM. Prediction of treatment outcome in social phobia: A cross-validation. Behav Res Ther 1999; 37: 659-70.
42. Slaap BR, van Vliet IM, Westenberg HG, Den Boer JA. Responders and non-responders to drug treatment in social phobia: Differences at baseline and prediction of response. J Affect Disord 1996; 39: 13-9.
43. Versiani M, Amrein R, Montgomery SA. Social phobia: Long-term treatment outcome and prediction of response - a moclobemide study. Int Clin Psychopharmacol 1997; 12: 239-54.
44. Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: An analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry 2002; 63: 152-5.
45. Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: A 12-year prospective study. Am J Psychiatry 2005; 162: 1179-87.
46. Geddes JR, Carney SM, Davies C et al. Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review. Lancet 2003; 361: 653-61.
47. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatr 2006; 51: 9S-91S
48. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9: 495-505.
49. Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003; 64: 250-8.
50. Feltner D, Wittchen HU, Kavoussi R, Brock J, Baldinetti F, Pande AC. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23: 18-28.
51. Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial. Eur Neuropsychopharmacol 2008; 18(9): 673-81.
52. Montgomery SA, Sheehan DV, Meoni P, Haudiquet V, Hackett D. Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. J Psychiatr Res 2002; 36: 209-17.
53. Food and Drug Administration [FDA]. New controversial clinical trial design gives better long-term data. FDA; 2006.
54. Connor KM, Davidson JR, Potts NL, Tupler LA, Miner CM, Malik ML, et al. Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 1998; 18: 373-8.
55. Walker JR, Van Ameringen MA, Swinson R, Bowen RC, Chokka PR, Goldner E, et al. Prevention of relapse in generalized social phobia: Results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 2000; 20: 636-44.
56. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: A 24-week study. Arch Gen Psychiatry 2002; 59: 1111-8.
57. Montgomery SA, Nil R, Durr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270-8.
58. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D. Paroxetine treatment of generalized anxiety disorder: A double-blind, placebo-controlled study. Am J Psychiatry 2003; 160: 749-56.
59. Rickels K, Pollack MH, Sheehan DV, Haskins JT. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000; 157: 968-74.
60. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001; 179: 15-22.
61. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiatry 2007; 40: 163-8.
62. Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 2006; 3: CD006115.
63. Mendels J, Krajewski TF, Huffer V et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 1986; 47: 170-4.
64. Bandelow B, Bobes J, Ahokas A, Eggens I, Liu S, Brecher M. Results from a phase III study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder. Int J Psychiatry Clin Pract 2007; 11: 314-5 (abstract).
65. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study. J Clin Psychiatry 2005; 66: 1321-5.
66. Pollack MH, Simon NM, Fagiolini A, Pitman R, McNally RJ, Nierenberg AA, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study. Biol Psychiatry 2006; 59: 211-5.
67. Stein DJ, Ahokas A, Fabiano A. Agomelatine in generalized anxiety disorder: A randomized, placebo-controlled, study. Eur Neuropsychopharmacol 2007; 17 (Suppl 4): S509-S510.
68. Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Rüther E. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatr 2007; 8: 175-87.
69. Woelk H, Arnoldt KH, Kieser M, Hoerr R. Ginkgo biloba special extract EGb 761 in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. J Psychiatr Res 2007; 41: 472-80.
70. Herrera-Arellano A, Jiménez-Ferrer E, Zamilpa A, Morales-Valdéz M, Garcia-Valencia CE, Tortoriello J. Efficacy and tolerability of a standardized herbal product from Galphimia glauca on generalized anxiety disorder. A randomized, double-blind clinical trial controlled with lorazepam. Planta Med 2007; 73: 713-7.
71. Blomhoff S, Haug TT, Hellström K, Holme I, Humble M, Madsbu HP, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 2001; 179: 23-30.
72. Clark DM, Ehlers A, McManus F, Hackmann A, Fennell M, Campbell H, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 2003; 71: 1058-67.
73. Davidson JR, Foa EB, Huppert JD, Keefe FJ, Franklin ME, Compton JS, et al. Fluoxetine, comprehensive cognitive behavioral therapy (CCBT) and placebo in generalized social anxiety disorder. Arch Gen Psychiatry 2004; 61: 1005-13.
74. Altamura AC, Pioli R, Vitto M, Mannu P. Venlafaxine in social phobia: A study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol 1999; 14: 239-45.
75. Van Ameringen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996; 8; 115-21.
76. Stein MB, Sareen J, Hami S, Chao J. Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158: 1725-27.
77. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry. 2006; 63: 298-304.
78. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 2003; 26: 457-94.
79. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development. Schizophr Bull 2003; 29: 15-31.
80. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87.
81. Baldwin DS. Sexual dysfunction associated with antidepressant drugs. Exp Opin Drug Safety 2004; 3: 457-470.
82. Baldwin DS, Bridgman K, Buis C. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. J Psychopharmacol 2006; 20: 91-6.
83. Baldwin DS, Moreno R, Briley M. Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Hum Psychopharmacol 2008; [Epub ahead of print].
84. Ferguson JM. SSRI antidepressant medications: Adverse effects and tolerability. Prim Care J Clin Psychiatry 2001; 3: 22-7.
85. Sussman N, Ginsberg D. Rethinking side effects of the selective serotonin reuptake inhibitors: Sexual dysfunction and weight gain. Psychiatr Ann 1998; 28: 89-97.
86. De Wilde J, Spiers R, Mertens C, Bartholomé F, Schotte G, Leyman S. A double-blind, comparative, multicenter study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87: 141-5.
87. Carney CE, Segal ZV, Edinger JD, Krystal AD. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatr 2007 68: 254-260.
88. Cervena K, Matousek M, Prasko J, Brunovsky M, Paskova B. Sleep disturbances in patients treated for panic disorder. Sleep Med 2005; 6: 149-153.
89. Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37: 9-15.
90. Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2007; 10: 73-84.
91. Chen Z, Yang J, Tobak A. Designing new treatments for depression and anxiety. IDrugs 2008; 11(3): 189-97.
92. Cunha RA, Ferre S, Vaugeois JM, Chen JF. Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders. Curr Pharm Des 2008; 14(15): 1512-24.
93. Gur A, Oktayoglu P. Central nervous system abnormalities in fibromyalgia and chronic fatigue syndrome: New concepts in treatment. Curr Pharm Des 2008; 14(13): 1274-94.